Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02163499 · ClinicalTrials.gov registry record · Phase 3

Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months

A Phase 3 study, sponsored by ZS Pharma.

Completed
Registry status
Phase 3
Development phase
751
Enrollment target

NCT02163499 is a Phase 3 study that has completed, run by ZS Pharma. The registered enrollment target is 751 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02163499, a Phase 3 study, has completed, sponsored by ZS Pharma.

COMPLETED
Registry status
Phase 3
Development phase
751 participants
Enrollment target

Study Summary

The Open-Label Maintenance Study contains an Acute Phase, in which subjects will be dosed with ZS 10 g three times daily (tid) for 24 to 72 hours, followed by a long-term Maintenance Phase.

Interventions

  • DRUG Sodium Zirconium Cyclosilicate

Trial Details

FieldValue
Enrollment Target 751 participants
Start Date 2014-06-30
Est. Completion 2016-11-30
Phase Phase 3

Sponsor

ZS Pharma

8 total trials

What the Registry Record Tells You About NCT02163499

The ClinicalTrials.gov registry entry for NCT02163499 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 751 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZS Pharma, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Sodium Zirconium Cyclosilicate is the first listed.

NCT02163499 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02163499 about?

NCT02163499 is a clinical study titled "Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months". The Open-Label Maintenance Study contains an Acute Phase, in which subjects will be dosed with ZS 10 g three times daily (tid) for 24 to 72 hours, followed by a long-term Maintenance Phase.

What is the current status of trial NCT02163499?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 751 participants. The study started on 2014-06-30. Estimated completion is 2016-11-30.

What interventions are being tested in trial NCT02163499?

The interventions under investigation include: Sodium Zirconium Cyclosilicate (DRUG).

Who is sponsoring clinical trial NCT02163499?

This trial is sponsored by ZS Pharma, which has 8 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.